Thursday, 15 October 2026European Markets

ABG SUNDAL COLLIER And FBD HOLDINGS PLC Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - ABG SUNDAL COLLIER (ABG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
ABG SUNDAL COLLIER (ABG.OL) kr6.42 9.65% 24.73%
FBD HOLDINGS PLC (EG7.IR) €13.05 7.41% 14.85%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ABG SUNDAL COLLIER (ABG.OL)

9.65% Forward Dividend Yield and 24.73% Return On Equity

ABG Sundal Collier Holding ASA, together with its subsidiaries, provides investment banking, stock broking, and corporate advisory services in Norway, Sweden, Denmark, and internationally. The company offers corporate financing services for corporate clients for raising capital through equity or debt financing. It also provides advisory services in mergers, acquisitions, and sales, as well as various real asset transactions and other advisory services. In addition, the company offers research and brokerage services comprising secondary security brokerage and research services. ABG Sundal Collier Holding ASA was founded in 1984 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ABG SUNDAL COLLIER has a trailing twelve months EPS of kr0.42.

PE Ratio

ABG SUNDAL COLLIER has a trailing twelve months price to earnings ratio of 15.29. Meaning, the purchaser of the share is investing kr15.29 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.73%.

More news about ABG SUNDAL COLLIER.

2. FBD HOLDINGS PLC (EG7.IR)

7.41% Forward Dividend Yield and 14.85% Return On Equity

FBD Holdings plc, through its subsidiaries, engages in the underwriting of general insurance to farmers, private individuals, and business owners in Ireland. The company operates in three segments: General Insurance, Financial Services, and Other Group Activities. It offers motor, property, liability and personal accident, home, travel, life and pension, business, farm, and business insurance products. The company also provides investment, pension brokerage, and employee services; engages in reinsurance activities; and operates as an intermediary for general, life, and pensions. FBD Holdings plc was founded in 1969 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, FBD HOLDINGS PLC has a trailing twelve months EPS of €1.9.

PE Ratio

FBD HOLDINGS PLC has a trailing twelve months price to earnings ratio of 6.87. Meaning, the purchaser of the share is investing €6.87 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.85%.

Volume

Today's last reported volume for FBD HOLDINGS PLC is 4616 which is 90.56% below its average volume of 48901.

Moving Average

FBD HOLDINGS PLC's value is below its 50-day moving average of €13.31 and above its 200-day moving average of €12.26.

More news about FBD HOLDINGS PLC.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com